Executive Summary
PetVivo Holdings reported a Q3 2025 revenue of $583,313, up to a modest extent on a QoQ basis but down 2.1% year over year (YoY). The company delivered a gross profit of $521,816 with a very high gross margin of 89.5%, illustrating favorable product economics on the revenue recognized. However, operating expenses remained outsized relative to top-line, yielding an EBITDA loss of $1.70 million and a net loss of $1.76 million for the quarter. Diluted earnings per share stood at -$0.085, reflecting aggressive investment in infrastructure and pipeline development without commensurate near-term revenue scale. Cash burn persists: net cash used in operating activities was $0.96 million, leaving cash on hand at $28,891 at quarter-end and net debt of roughly $2.34 million against total assets of $3.11 million, signaling an ongoing funding requirement. On the positive side, the gross margin strength indicates that a scalable revenue ramp or disciplined cost management could drive a clearer path to profitability if PETV can convert pipeline opportunities and licenses into meaningful revenue.
Key Performance Indicators
QoQ: 190.61% | YoY:-2.11%
QoQ: 190.61% | YoY:26.41%
Key Insights
Revenue: $583,313; YoY -2.11%; QoQ +190.61%
Gross Profit: $521,816; YoY +26.41%; QoQ +190.61%; Gross Margin: 0.895
Operating Income: -$1,758,405; YoY +17.59%; QoQ +19.08% (both negative)
EBITDA: -$1,700,586; EBITDA Margin: -2.92%
Net Income: -$1,757,038; Net Margin: -3.01%
EPS: -$0.0852; Weighted Avg Shs Out: 20,632,921
Cash from Operations: -$961,216; Free Cash Flow: -$984,848
Cash and Cash Equivalents: $28,891; Total Debt: $2,368,386; Net Debt: $2,339,495
Current Ratio: 0.418; Quick Ratio: 0.2...
Financial Highlights
Revenue: $583,313; YoY -2.11%; QoQ +190.61%
Gross Profit: $521,816; YoY +26.41%; QoQ +190.61%; Gross Margin: 0.895
Operating Income: -$1,758,405; YoY +17.59%; QoQ +19.08% (both negative)
EBITDA: -$1,700,586; EBITDA Margin: -2.92%
Net Income: -$1,757,038; Net Margin: -3.01%
EPS: -$0.0852; Weighted Avg Shs Out: 20,632,921
Cash from Operations: -$961,216; Free Cash Flow: -$984,848
Cash and Cash Equivalents: $28,891; Total Debt: $2,368,386; Net Debt: $2,339,495
Current Ratio: 0.418; Quick Ratio: 0.297; Cash Ratio: 0.0098
Book Value per Share: Negative; Price-to-Sales (trailing): 21.93; Revenue per Share: 28.28c
Note: All figures in USD thousands except per-share figures; quarter referenced is Q3 2025.
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Revenue |
583.31K |
-2.11% |
190.61% |
| Gross Profit |
521.82K |
26.41% |
190.61% |
| Operating Income |
-1.76M |
17.59% |
19.08% |
| Net Income |
-1.76M |
-0.41% |
19.23% |
| EPS |
-0.09 |
29.00% |
22.55% |
Key Financial Ratios
operatingProfitMargin
-301%
operatingCashFlowPerShare
$-0.05
freeCashFlowPerShare
$-0.05
Management Commentary
No earnings call transcript data provided in the material. Management commentary and specific quotes from a QQ3 2025 call are therefore not available for inclusion. Key themes to obtain from future disclosures would include strategy for Spryng adoption, progress on the product pipeline, and the company’s plan to stabilize liquidity and manage operating costs.
Forward Guidance
No formal forward guidance was disclosed in the provided materials. Given the liquidity constraints (cash of $28.9k) and persistent cash burn, PETV’s near-term trajectory hinges on (1) accelerated revenue growth from Spryng adoption and licensing of pipeline devices, (2) cost discipline to reduce operating expenditures, and (3) securing additional financing or strategic partnerships. Potential catalysts to monitor include (a) customer adoption metrics for Spryng in veterinary clinics, (b) progress and regulatory clearance for pipeline devices, and (c) any announced licensing or collaboration agreements that could unlock scalable revenue streams. Investors should monitor quarterly operating cash flow trends, gross margin sustainability at higher volumes, and the company’s ability to extend its cash runway through financing or partnerships.